Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023
Next Generation Cardiovascular Biotech to Present non-clinical Data on Two of its Novel, Potent, and Highly Selective CaMKII Inhibitors First Company to Study a CaMKII Inhibitor in a Clinical Trial BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the […]
